Janux TherapeuticsJANX +0.85%46 Quick Ratio is 17.01 as of Mar. 2026, which is 42% below its 10-year median of 29.14. GuruFocus rates JANX with a GF Score™ of 46/100 and a GF Value™ of $39.28 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,412 Biotechnology companies, Janux Therapeutics ranks better than 89.38% on this metric.
Janux Therapeutics has a quick ratio of 17.01. It generally indicates good short-term financial strength.
The historical rank and industry rank for Janux Therapeutics's Quick Ratio or its related term are showing as below:
JANX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.14 Med: 29.14 Max: 62.09
Current: 17.01
During the past 7 years, Janux Therapeutics's highest Quick Ratio was 62.09. The lowest was 0.14. And the median was 29.14.
JANX's Quick Ratio is ranked better than 89.38% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs JANX: 17.01
Janux Therapeutics (NAS:JANX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Janux Therapeutics Quick Ratio Related Terms
Janux Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Janux Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Janux Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Janux Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Janux Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Janux Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Janux Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Janux Therapeutics (JANX) has a Quick Ratio of 17.01 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Janux Therapeutics and its competitors. This is 42% below median its historical median of 29.14. Over the past decade, Janux Therapeutics' Quick Ratio has ranged from 0.14 to 62.09. According to the industry distribution chart, Janux Therapeutics ranks #150 out of 1412 companies in the Biotechnology industry, placing it in the top 10.6%.
Is Janux Therapeutics' Quick Ratio too high?
Janux Therapeutics' current Quick Ratio of 17.01 is 42% below median its 10-year median of 29.14. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 62.09. The Biotechnology industry median Quick Ratio is 3.60. Janux Therapeutics' value of 17.01 is 372.5% above this industry median. Based on the distribution chart, Janux Therapeutics ranks #150 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Janux Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Janux Therapeutics' Quick Ratio compare to SLDB and TBPH?
According to the Biotechnology industry distribution chart, Janux Therapeutics ranks #150 out of 1412 companies for Quick Ratio. This places Janux Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Janux Therapeutics' value of 17.01 is 372.5% above this benchmark. Historically, Janux Therapeutics' own Quick Ratio has ranged from 0.14 to 62.09 over the past decade. While the company's 10-year median is 29.14 vs. the industry median of 3.60, Janux Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Janux Therapeutics's current Quick Ratio of 17.01 is 372.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Janux Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Janux Therapeutics's current Quick Ratio is 17.01, which is 42% below median its own 10-year median of 29.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Janux Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Janux Therapeutics (JANX) is currently considered Possible Value Trap. The stock's GF Value™ is $39.28, compared to a current price of $15.45 — trading 60.7% below its estimated fair value. The current Quick Ratio is 17.01, which is 42% below median its 10-year median of 29.14 and 372.5% above the Biotechnology industry median of 3.60. Janux Therapeutics' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Janux Therapeutics (JANX), the current Quick Ratio is 17.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Janux Therapeutics (JANX) Overvalued in 2026?
Based on GuruFocus' analysis, Janux Therapeutics stock appears to be undervalued.
The current stock price of $15.45 is trading 60.7% below its estimated GF Value™ of $39.28.
GuruFocus considers Janux Therapeutics to be Possible Value Trap.
Key valuation signals for JANX:
Quick Ratio: 17.01 (42% below median its 10-year median of 29.14)
GF Value™: $39.28 vs. price of $15.45 (60.7% below fair value)
Industry Position: 372.5% above the Biotechnology median (#150 of 1412)
No single metric tells the full story. See the JANX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
46GF Score
Get the complete analysis for JANX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JANX has been successfully added to your 
